$GNPX
Genprex Inc

2021 Q4 Form 10-Q Financial Statement

#000143774921026629 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.196M $2.000M $2.900M
YoY Change -24.29% 40.88% 50.26%
% of Gross Profit
Research & Development $3.480M $1.432M $2.320M
YoY Change 50.01% 6.07% 373.47%
% of Gross Profit
Depreciation & Amortization $6.950K $6.489K $0.00
YoY Change 13.56%
% of Gross Profit
Operating Expenses $5.683M $1.432M $5.230M
YoY Change 8.66% 6.07% 115.23%
Operating Profit -$3.439M
YoY Change 23.81%
Interest Expense $990.00 $1.060K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.682M -$3.438M -$5.230M
YoY Change 8.64% 24.11% 116.12%
Income Tax
% Of Pretax Income
Net Earnings -$5.682M -$3.438M -$5.230M
YoY Change 8.64% 23.89% 116.12%
Net Earnings / Revenue
Basic Earnings Per Share -$0.07
Diluted Earnings Per Share -$118.8K -$72.21K -$131.8K
COMMON SHARES
Basic Shares Outstanding 47.81M 47.53M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.63M $42.02M $27.32M
YoY Change 41.39% 99.53% 1266.0%
Cash & Equivalents $38.63M $42.02M $27.32M
Short-Term Investments
Other Short-Term Assets $511.4K $749.0K $380.0K
YoY Change 34.57% -22.78% 123.53%
Inventory $2.875M $3.010M
Prepaid Expenses
Receivables $0.00 $127.00 $127.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $39.14M $45.64M $27.70M
YoY Change 41.28% 100.98% 830.73%
LONG-TERM ASSETS
Property, Plant & Equipment $48.61K $44.34K $39.44K
YoY Change 23.24% 4.73% -11.67%
Goodwill
YoY Change
Intangibles $642.4K $627.4K $601.6K
YoY Change 6.77% 6.75% 22.48%
Long-Term Investments
YoY Change
Other Assets $3.673M $638.1K $3.623M
YoY Change 1.38% 6.63% 606.41%
Total Long-Term Assets $3.722M $682.4K $3.663M
YoY Change 1.62% 6.5% 556.91%
TOTAL ASSETS
Total Short-Term Assets $39.14M $45.64M $27.70M
Total Long-Term Assets $3.722M $682.4K $3.663M
Total Assets $42.86M $46.33M $31.37M
YoY Change 36.65% 98.39% 787.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $973.2K $591.9K $190.0K
YoY Change 412.21% 84.98% -56.82%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $260.0K
YoY Change -100.0% 271.43%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.585M $1.162M $450.7K
YoY Change 251.72% 209.3% -11.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.585M $1.162M $450.7K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.585M $1.162M $450.0K
YoY Change 252.29% 205.76% -11.76%
SHAREHOLDERS EQUITY
Retained Earnings -$78.02M -$72.34M -$58.42M
YoY Change 33.54% 35.99% 44.33%
Common Stock $47.87K $47.80K $43.12K
YoY Change 11.03% 21.13% 123.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $41.28M $45.17M $30.92M
YoY Change
Total Liabilities & Shareholders Equity $42.86M $46.33M $31.37M
YoY Change 36.65% 98.39% 787.53%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income -$5.682M -$3.438M -$5.230M
YoY Change 8.64% 23.89% 116.12%
Depreciation, Depletion And Amortization $6.950K $6.489K $0.00
YoY Change 13.56%
Cash From Operating Activities -$3.218M -$2.635M -$3.900M
YoY Change -17.49% 31.08% 126.74%
INVESTING ACTIVITIES
Capital Expenditures -$26.22K -$19.03K -$20.00K
YoY Change 31.1% -61.94% -80.0%
Acquisitions
YoY Change
Other Investing Activities -$147.4K $187.3K -$2.330M
YoY Change -93.68% -10.8%
Cash From Investing Activities -$173.6K $168.3K -$2.340M
YoY Change -92.58% 12.19% 2500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 243.5K 12.50M
YoY Change -100.0% -69.17% 884.25%
NET CHANGE
Cash From Operating Activities -3.218M -2.635M -3.900M
Cash From Investing Activities -173.6K 168.3K -2.340M
Cash From Financing Activities 0.000 243.5K 12.50M
Net Change In Cash -3.392M -2.223M 6.260M
YoY Change -154.18% 107.75% -1259.26%
FREE CASH FLOW
Cash From Operating Activities -$3.218M -$2.635M -$3.900M
Capital Expenditures -$26.22K -$19.03K -$20.00K
Free Cash Flow -$3.192M -$2.616M -$3.880M
YoY Change -17.74% 33.46% 139.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47808570
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47803570
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47803570
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43117681
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43117681
CY2011 gnpx Proceeds From State Of Texas Emerging Technology Fund Award
ProceedsFromStateOfTexasEmergingTechnologyFundAward
2250000 USD
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q2 gnpx Nonvoting To Voting Common Stock Conversion Ratio
NonvotingToVotingCommonStockConversionRatio
1 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42020527 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27319685 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
127 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
127 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
749029 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
384553 USD
CY2021Q3 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
2875046 USD
CY2020Q4 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
3011042 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
45644729 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
30715407 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44342 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
39441 USD
CY2021Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10741 USD
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10741 USD
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
627360 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
601625 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
638101 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
612366 USD
CY2021Q3 us-gaap Assets
Assets
46327172 USD
CY2020Q4 us-gaap Assets
Assets
31367214 USD
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
591941 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
192968 USD
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
569952 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
257756 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1161893 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
450724 USD
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
47803 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
43118 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
117453401 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
89295600 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72335925 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
45165279 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
30916490 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58422228 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46327172 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31367214 USD
CY2021Q3 us-gaap Revenues
Revenues
0 USD
CY2020Q3 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
CY2021Q3 us-gaap Depreciation
Depreciation
6489 USD
CY2020Q3 us-gaap Depreciation
Depreciation
5714 USD
us-gaap Depreciation
Depreciation
15579 USD
us-gaap Depreciation
Depreciation
16843 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1431999 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1350016 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5127419 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4983530 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2000437 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1421863 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8774844 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7731550 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
3438925 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
2777593 USD
us-gaap Costs And Expenses
CostsAndExpenses
13917842 USD
us-gaap Costs And Expenses
CostsAndExpenses
12731923 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3438925 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2777593 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13917842 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12731923 USD
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1060 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2650 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
4146 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
17467 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3437865 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2774943 USD
us-gaap Net Income Loss
NetIncomeLoss
-13913696 USD
us-gaap Net Income Loss
NetIncomeLoss
-12714456 USD
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47612419
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39055159
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46851241
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34139991
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3023545 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25731640 USD
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1550 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
752444 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5566220 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
23942959 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2569226 USD
CY2020Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
11000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2359621 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4373293 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
24509513 USD
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
793531 USD
CY2020Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
15350 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
432590 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2774943 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
22976041 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
30916490 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25324330 USD
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
20650 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
651088 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6489714 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
50422845 USD
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
110033 USD
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
21100 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1116359 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3986118 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
47684219 USD
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
243548 USD
CY2021Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
16800 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
658577 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3437865 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
45165279 USD
us-gaap Net Income Loss
NetIncomeLoss
-13913696 USD
us-gaap Net Income Loss
NetIncomeLoss
-12714456 USD
us-gaap Depreciation
Depreciation
15579 USD
us-gaap Depreciation
Depreciation
16843 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2484574 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3572439 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-570 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
364476 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
783401 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
398973 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-114834 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
312196 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-20195 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11066850 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10043034 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20480 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14529 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
25735 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
96512 USD
gnpx Payments For Proceeds From Research And Development Supplies
PaymentsForProceedsFromResearchAndDevelopmentSupplies
-135996 USD
gnpx Payments For Proceeds From Research And Development Supplies
PaymentsForProceedsFromResearchAndDevelopmentSupplies
-115456 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
89781 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4415 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25677911 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29094513 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25677911 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29094513 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14700842 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19055894 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27319685 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2002492 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42020527 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21058386 USD
CY2018Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
6.6841954 pure
CY2018Q1 gnpx Capital Stock Shares Authorized
CapitalStockSharesAuthorized
210000000
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Use of Estimates</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of our unaudited condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p>
CY2021Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
41770489 USD
CY2020Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
27091596 USD
CY2021Q3 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
2875046 USD
CY2020Q4 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
3011042 USD
CY2010Q4 gnpx State Of Texas Emerging Technology Fund Award Amount
StateOfTexasEmergingTechnologyFundAwardAmount
4500000 USD
CY2010 gnpx Proceeds From State Of Texas Emerging Technology Fund Award
ProceedsFromStateOfTexasEmergingTechnologyFundAward
2250000 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
670889
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
677912 USD
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
15000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
58550 USD
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1277743
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1320155 USD
CY2020 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5511599
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2537731 USD
CY2020 gnpx Stock Issued During Period Shares Exercise Of Cashless Warrants
StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants
199630
CY2020 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
51432
CY2020 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
154648 USD
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47803570
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7476056
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.45
CY2020 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
550000
CY2020 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
2.41
CY2020 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
44528
CY2020 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
0.50
CY2020 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
5826781
CY2020 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
0.47
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2154747
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.37
gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
50000
gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
5.29
gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
-0
gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
0
gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
-0
gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
0
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2204747
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.39
CY2021Q3 gnpx Class Of Warrant Or Right Vested Or Expected To Vest
ClassOfWarrantOrRightVestedOrExpectedToVest
41665
CY2021Q3 gnpx Class Of Warrant Or Right Vested Or Expected To Vest Weighted Average Exercise Price
ClassOfWarrantOrRightVestedOrExpectedToVestWeightedAverageExercisePrice
3.54
CY2021Q3 gnpx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
1971412
CY2021Q3 gnpx Class Of Warrant Or Right Exercisable Exercise Price
ClassOfWarrantOrRightExercisableExercisePrice
4.62
CY2020 gnpx Stock Issued During Period Shares Warrants Issued
StockIssuedDuringPeriodSharesWarrantsIssued
5511599
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2537731 USD
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
315182
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8682808
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2519628
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
10000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.22
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
670889
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2466529
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
327640
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1277743
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M2D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y21D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5982923
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.66
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2466529
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.87
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1277743
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.03
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
327640
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.31
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6844069
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2519628
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.26
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
670889
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
10000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.22
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8682808
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.36
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
349239
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.91
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4894439
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.10

Files In Submission

Name View Source Status
0001437749-21-026629-index-headers.html Edgar Link pending
0001437749-21-026629-index.html Edgar Link pending
0001437749-21-026629.txt Edgar Link pending
0001437749-21-026629-xbrl.zip Edgar Link pending
ex_279494.htm Edgar Link pending
ex_279495.htm Edgar Link pending
ex_279496.htm Edgar Link pending
ex_295742.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gnpx-20210930.xsd Edgar Link pending
gnpx-20210930_cal.xml Edgar Link unprocessable
gnpx-20210930_def.xml Edgar Link unprocessable
gnpx-20210930_lab.xml Edgar Link unprocessable
gnpx-20210930_pre.xml Edgar Link unprocessable
gnpx20210930_10q.htm Edgar Link pending
gnpx20210930_10q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending